U.S. Water Utilities Stock News

Why the upcoming TN-401 data matters for Tenaya Therapeutics stock Tenaya Therapeutics (TNYA) is drawing attention as investors look ahead to new clinical safety and efficacy data for TN-401, its gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy, at the ASGCT 2026 meeting. This late breaking oral presentation, together with additional abstracts on Tenaya’s gene therapy and gene editing programs, gives you fresh information to evaluate the company’s pipeline...

Brixmor Property Group Inc. recently reported first-quarter 2026 results showing year-on-year growth in revenue to US$354.82 million and net income to US$127.75 million, while also updating full-year guidance to net income of US$355 million to US$365 million and diluted EPS of US$1.16 to US$1.19. Alongside the earnings update, the board affirmed a quarterly dividend of US$0.3075 per share and highlighted that 2026 uncollectible revenues are expected to remain contained at 75 to 100 basis...

Sarepta Therapeutics (NasdaqGS:SRPT) is progressing its small interfering RNA (siRNA) candidates SRP-1001 and SRP-1003, with early data viewed as encouraging. The company is seeking to transition AMONDYS 45 and VYONDYS from accelerated to traditional FDA approvals through recent regulatory submissions. These updates come as Sarepta refines its commercial focus beyond gene therapy Elevidys, which continues to face regulatory and commercial complexity. Sarepta Therapeutics focuses on rare...

Wendy's (NasdaqGS:WEN) has announced a major franchise agreement to open up to 1,000 restaurants in China over the next decade. The expansion is part of its "Project Fresh" turnaround plan and is intended to offset weaker U.S. same-restaurant sales. The deal marks a shift in focus toward international markets as the company looks for new long term growth drivers. Wendy's, trading at around $6.95, has seen extended share price pressure, with the stock down 14.9% year to date and 39.1% over...

If you are wondering whether Chevron at around US$182.50 is offering fair value or if you are paying up for the story, this article walks through what the numbers are actually saying about the stock. The share price has pulled back recently, with a 5.6% decline over the last 7 days and a 9.4% decline over the last 30 days, while still showing returns of 17.1% year to date and 39.2% over 1 year. Recent headlines around Chevron have focused on broad energy sector sentiment and ongoing interest...

CoStar Group (NasdaqGS:CSGP) is set to be removed from the Nasdaq-100 Index. The change affects the stock's role in one of the most followed US equity benchmarks. Index adjustments can influence passive fund holdings and trading activity in the shares. For investors watching CoStar Group, the index removal intersects with a share price that most recently closed at $34.98. The stock has recorded a 1.1% return over the past week, alongside longer term declines of 11.4% over 30 days, 46.7%...

Wondering if AMETEK at around US$234.73 is offering fair value or if you might be paying up for quality? This article breaks down what the current price could mean for you. The stock has been relatively flat over the last 7 days with a 0.3% decline, but sits on gains of 7.8% over 30 days, 12.2% year to date and 37.7% over 1 year. This naturally raises questions about how much of the story is already priced in. Recent coverage has focused on AMETEK's position in the capital goods space and...

This article examines whether Energizer Holdings, at US$18.56, could be a bargain or a value trap, and explains what the current share price might be implying. The stock has recently seen mixed returns, with an 11.1% gain over the last 30 days but declines of 5.2% over 7 days, 6.9% year to date, and 11.5% over 1 year, extending to 39.8% over 3 years and 52.2% over 5 years. Recent coverage has focused on how Energizer Holdings fits into the broader household products sector, as investors...

AdvanSix (ASIX) closed out FY 2025 with Q4 revenue of US$359.9 million and a basic EPS loss of US$0.10. The trailing twelve months show EPS of US$1.83 on revenue of about US$1.5 billion. Over recent periods, revenue has moved from US$329.1 million in Q4 2024 to US$410.0 million in Q2 2025. Quarterly EPS has ranged from a small profit of US$0.01 in Q4 2024 to a high of US$1.17 in Q2 2025, giving investors a mix of profitable quarters and losses at the year end. With net profit margin at 3.2%...

In early May 2026, Wall Street analysts projected that American Public Education’s quarterly earnings per share would rise by very large year-over-year and revenue would increase by 5.6%, supported by improved student enrollment and net course registrations at Rasmussen University and Hondros College. These forecasts, alongside American Public University System’s recent commencement celebrating more than 17,700 graduates, highlight growing operational momentum across the company’s core...

Recent performance snapshot Penumbra (PEN) has drawn investor attention after recent trading, with the stock last closing at US$324.65. Short term moves have been mixed, with a small 1 day gain alongside a slight 7 day decline. See our latest analysis for Penumbra. Looking past the latest move, Penumbra’s recent share price return has been softer, with a 90 day decline of 4.8%. However, the year to date share price return of 4.92% sits alongside a 12.44% total shareholder return over the last...

John Wiley & Sons (WLY) has reshaped its leadership in Research by appointing Jessica Kowalski as Executive Vice President and General Manager, following the departure of Jay Flynn, who helped shape the segment’s direction. See our latest analysis for John Wiley & Sons. The leadership moves around AI and research publishing come as WLY’s share price sits at US$40.70, with a 30 day share price return of 6.38% and a 90 day share price return of 39.19%, while the 1 year total shareholder return...

AGI (NYSE:AGBK) has filed a substantial Shelf Registration tied to an Employee Stock Ownership Plan for a large block of Class A common shares. The filing outlines a framework for issuing ESOP related shares over time, which can influence the company’s capital structure and employee ownership levels. AGI, trading at $7.39, has had mixed recent performance, with the stock up 4.2% over the past week and 9.5% over the past month, while showing a 31.3% decline year to date. The new ESOP related...

Oppenheimer Holdings Inc. reported first-quarter 2026 results, with revenue rising to US$445.1 million from US$367.83 million a year earlier, but swinging from net income of US$30.66 million to a net loss of US$20.58 million, and moving from basic earnings per share of US$2.93 to a basic loss of US$1.93. Despite this shift to a loss, the company also announced a quarterly dividend of US$0.20 per share payable on May 29, 2026, indicating continued cash returns to shareholders even as...

American Bitcoin stock moves after recent trading swing American Bitcoin (ABTC) has drawn fresh attention after a recent trading swing, with the stock closing at US$1.16 and carrying a market value of about US$1.33b in the US listed Bitcoin mining space. See our latest analysis for American Bitcoin. The recent 7.2% one-day share price decline comes after a 33.1% 30-day share price return, while the year-to-date share price return of 34.83% suggests momentum has been fading over a longer...

In late April 2026, O-I Glass, Inc. reported first-quarter 2026 results showing sales of US$1,540 million, down from US$1,567 million a year earlier, and a wider net loss of US$73 million versus US$16 million, with basic and diluted loss per share from continuing operations both at US$0.48 compared to US$0.10 previously. This sharp increase in quarterly loss, despite only a modest sales decline, raises questions about cost pressures and profitability trends across O-I Glass's...

Wondering if Fox at around US$62.69 is priced for opportunity or already reflects the story? This piece walks through the key numbers to help you frame that question clearly. The stock has seen mixed recent returns, with a 1.3% decline over the last week, a 5.1% gain over the last 30 days, a 15.0% decline year to date and a 25.5% return over the last year, alongside longer term returns of 112.3% over three years and 72.6% over five years. Recent market interest has been shaped by ongoing...

If you are wondering whether American States Water at around US$76.84 is priced fairly or offering value, it helps to step back and look at what the recent share performance and fundamentals are signaling. Over the short term the stock is up 2.1% over the last week and is roughly flat over the past month with a 0.1% decline, while year to date it is up 6.3% and the 1 year return sits at a 1.8% decline. These moves come as investors continue to react to company specific developments and the...

Halozyme Therapeutics (NasdaqGS:HALO) has entered a new global collaboration with GSK to apply its ENHANZE technology to subcutaneous delivery of multiple oncology products. The agreement includes development of subcutaneous formulations for antibody drug conjugates, expanding ENHANZE into a new class of cancer therapies. The collaboration introduces additional potential royalty streams tied to future use of ENHANZE across GSK’s oncology portfolio. Halozyme Therapeutics, trading at $65.19,...

RPM International (RPM) drew fresh attention after reporting third quarter fiscal 2026 earnings and sales that exceeded expectations, alongside guidance regarding sales and adjusted EBIT. See our latest analysis for RPM International. The share price has eased back recently, with a 1 month share price return of 4.84% but a 90 day share price return decline of 13.30%, while the 1 year total shareholder return decline of 6.79% contrasts with a 3 year total shareholder return of 32.76%. This...

Investors may be wondering if Phibro Animal Health at around US$43.16 is still offering value after a strong run, or if the easy gains are behind it. The stock has pulled back 18.8% over the last week and 22.5% over the last month, yet it still shows a 15.7% gain year to date and a 96.6% return over the past year. These sharp moves are drawing attention back to what is already priced into Phibro Animal Health and how much of its story is reflected in the current share price. Ongoing interest...

Zai Lab (NasdaqGM:ZLAB) reported new clinical data from its global oncology and immunology pipeline, including intracranial response data for zoci in small cell lung cancer. The company is preparing to launch KarXT in China for schizophrenia in the next quarter. Management highlighted these pipeline and launch updates while also flagging near term revenue pressure. Zai Lab focuses on developing and commercializing medicines in oncology and immunology, as well as central nervous system...

If you are wondering whether Bruker stock is priced attractively or already reflects its prospects, the recent share moves make that question especially timely. The stock last closed at US$43.73, with returns of 19.1% over the past week and 19.3% over the past month, compared with an 8.5% gain over the past year and longer term returns over 3 and 5 years that have been negative. These shorter term gains come after a period where investors have been reassessing many life sciences and tools...

Wondering if Agilent Technologies at US$118.65 is offering solid value or just fair pricing right now? This article breaks down what the current market price might be implying. The stock is up 2.7% over the last week and 4.2% over the last month, even though the year to date return stands at a 14.0% decline and the 1 year return is 10.0%. Taken together, these figures provide a mixed picture of sentiment and recent momentum. Recent coverage has focused on how Agilent Technologies fits into...